Paul Campbell
Comptroller/Controller/Auditor chez VIATRIS INC.
Fortune : 2 M $ au 31/03/2024
Profil
Paul B.
Campbell is currently the Chief Accounting Officer & Controller at Viatris, Inc. He previously worked at Mylan NV as the Chief Accounting Officer, Interim CFO & Senior VP.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VIATRIS, INC.
0,01% | 05/03/2024 | 154 144 ( 0,01% ) | 2 M $ | 31/03/2024 |
Postes actifs de Paul Campbell
| Sociétés | Poste | Début |
|---|---|---|
| VIATRIS INC. | Comptroller/Controller/Auditor | 16/11/2020 |
Anciens postes connus de Paul Campbell
| Sociétés | Poste | Fin |
|---|---|---|
Mylan NV
 Mylan NV Pharmaceuticals: MajorHealth Technology Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom. | Director of Finance/CFO | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VIATRIS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Mylan NV
Mylan NV Pharmaceuticals: MajorHealth Technology Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom. | Health Technology |
